1. Home
  2. COGT vs LC Comparison

COGT vs LC Comparison

Compare COGT & LC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • LC
  • Stock Information
  • Founded
  • COGT 2014
  • LC 2006
  • Country
  • COGT United States
  • LC United States
  • Employees
  • COGT N/A
  • LC N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • LC Finance: Consumer Services
  • Sector
  • COGT Health Care
  • LC Finance
  • Exchange
  • COGT Nasdaq
  • LC Nasdaq
  • Market Cap
  • COGT 2.3B
  • LC 2.0B
  • IPO Year
  • COGT 2018
  • LC 2014
  • Fundamental
  • Price
  • COGT $16.30
  • LC $17.39
  • Analyst Decision
  • COGT Strong Buy
  • LC Strong Buy
  • Analyst Count
  • COGT 12
  • LC 6
  • Target Price
  • COGT $22.00
  • LC $19.67
  • AVG Volume (30 Days)
  • COGT 2.4M
  • LC 2.1M
  • Earning Date
  • COGT 10-31-2025
  • LC 10-22-2025
  • Dividend Yield
  • COGT N/A
  • LC N/A
  • EPS Growth
  • COGT N/A
  • LC 91.85
  • EPS
  • COGT N/A
  • LC 0.88
  • Revenue
  • COGT N/A
  • LC $1,296,102,000.00
  • Revenue This Year
  • COGT N/A
  • LC N/A
  • Revenue Next Year
  • COGT N/A
  • LC $15.53
  • P/E Ratio
  • COGT N/A
  • LC $19.69
  • Revenue Growth
  • COGT N/A
  • LC 16.98
  • 52 Week Low
  • COGT $3.72
  • LC $7.90
  • 52 Week High
  • COGT $17.15
  • LC $19.88
  • Technical
  • Relative Strength Index (RSI)
  • COGT 61.29
  • LC 55.58
  • Support Level
  • COGT $14.20
  • LC $16.80
  • Resistance Level
  • COGT $16.50
  • LC $19.88
  • Average True Range (ATR)
  • COGT 0.84
  • LC 0.86
  • MACD
  • COGT -0.07
  • LC 0.09
  • Stochastic Oscillator
  • COGT 71.19
  • LC 48.87

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About LC LendingClub Corporation

LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.

Share on Social Networks: